JPRN-UMIN000009753已完成2 期
Phase II study to determine the optimal number of aspirates during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of sarcoidosis - Optimal number of aspirates during EBUS-TBNA for the diagnosis of sarcoidosis
agoya Medical Center0 个研究点目标入组 90 人开始时间: 2013年1月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Serious concomitant medical illness 2. SPO2<90% with supplemental oxygen 3. Obvious bleeding tendency 4. Pregnancy 5. Other presumed difficulties for patients in this study
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate the safety, antitumour activity and determine the maximum tolerated dose of Debio 1143 combined with Chemo-Radiation Therapy in patients with advanced head and neck cancer.Patients with locally advanced squamous cell carcinoma of the head and neckMedDRA version: 14.1Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000044-25-FRDebiopharm S.A.116
进行中（未招募）
1 期
A study of ixazomib plus lenalidomide plus dexamethasoen (IRd) for newly diagnosed transplant-eligible myeloma patientsMultiple myeloma newly diagnosed transplant-eligible patientsMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-004863-35-LTHelsinki University Hospital Comprehensive Cancer Center Hematology120
进行中（未招募）
1 期
A study of ixazomib plus lenalidomide plus dexamethasone (IRd) for newly diagnosed transplant-eligible myeloma patientsMultiple myeloma newly diagnosed transplant-eligible patientsMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-004863-35-FIHospital District of Helsinki and Uusimaa/Helsinki University Hospital HUS120
进行中（未招募）
1 期
A study of ixazomib plus lenalidomide plus dexamethasoen (IRd) for newly diagnosed transplant-eligible myeloma patientsEUCTR2015-004863-35-SEHelsinki University Hospital Comprehensive Cancer Center Hematology120
进行中（未招募）
1 期
A study of ixazomib plus lenalidomide plus dexamethasoen (IRd) for newly diagnosed transplant-eligible myeloma patientsMultiple myeloma newly diagnosed transplant-eligible patientsMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-004863-35-NOHelsinki University Hospital Comprehensive Cancer Center Hematology120